Last month marked Women’s History Month, and in February there was International Day of Women and Girls in Science, too. But, ...
Oligonucleotide (oligo) therapies have been in development for decades. Recent advances in molecular design, chemistry, ...
The regulator has sent a complete response letter (CRL) to AbbVie for trenibotulinumtoxinE (TrenibotE), a follow-up to its ...
In addition to the three NPVs, the FDA also announced the approval of an IND submission for DemeRx, which is investigating ...
Sanofi's new chief executive, Belén Garijo, will see her tenure at the company kick-started by a strong 2026 first quarter, ...
In biotech, value is created at discrete moments – when data resolves uncertainty. Until then, risk remains. Every dollar ...
Clinical trial sponsors and contract research organisations (CROs) are expanding clinical trials internationally to access ...
The Telethon Undiagnosed Diseases Programme (TUDP), run by the Naples-based biomedical charity Fondazione Telethon, has ...
The phase 3 LITESPARK-012 trial is testing triplet therapy with oral HIF-2 alpha inhibitor Welireg (belzutifan) given ...
Regeneron has become the first company to get US approval for a gene therapy for congenital hearing loss, after the FDA gave ...
In this week's second major AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, designed to ...
Armed with new phase 3 data, Novo Nordisk has said it will file for approval of oral formulations of its GLP-1 agonist semaglutide as a treatment for type 2 diabetes (T2D) in children and adolescents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results